Ard van Veelen

4PUBLICATIONS
7CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Instrumental methods (excl. immunological and bioassay methods)Metabolomic chemistry
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Oct 16, 2023
Exploring the impact of patient-specific clinical features on osimertinib effectiveness in a real-world cohort of patients with EGFR mutated non-small cell lung cancer.

Ard van Veelen, G D Marijn Veerman, Marjon V Verschueren

|Jun 09, 2023
Durvalumab after chemoradiotherapy in patients with stage III non-small-cell lung cancer: real-world outcomes versus clinical trial results.

Marjon V Verschueren, Talitha Dijs, Judith L Gulikers

|Aug 07, 2021
Development and validation of an HPLC-MS/MS method to simultaneously quantify alectinib, crizotinib, erlotinib, gefitinib and osimertinib in human plasma samples, using one assay run.

Ard van Veelen, Robin van Geel, Roy Schoufs

|Dec 07, 2019
Validation of an analytical method using HPLC-MS/MS to quantify osimertinib in human plasma and supplementary stability results.

Ard van Veelen, Robin van Geel, Yvo de Beer

Pageof 1

Frequent Collaborators

1 joint publications

Marjon V Verschueren

1 joint publications

Judith L Gulikers

1 joint publications

Lizza El Hendriks

1 joint publications

Lourens T Bloem